STEP 3 Trial: Semaglutide Plus Intensive Behavioral Therapy for Weight Loss

What Exactly Did STEP 3 Test?

STEP 3 was a phase 3, randomized, double-blind, placebo-controlled trial published in JAMA on March 18, 2021, enrolling 611 adults with a BMI of at least 30 kg/m² or at least 27 kg/m² with one weight-related comorbidity, none of whom had type 2 diabetes. [1] The trial ran for 68 weeks and layered a 30-session intensive behavioral therapy protocol onto the standard semaglutide 2.4 mg dose-escalation schedule. Participants in both arms received the same counseling, the same initial 1,000-1,200 kcal/day meal plan for weeks one through eight, and the same maintenance meal plan thereafter.

The central question was whether combining the drug with structured behavior change would outperform the drug or the behavior program alone. Prior obesity pharmacotherapy trials almost never included this level of behavioral support, so STEP 3 filled a meaningful evidence gap. Semaglutide binds the GLP-1 receptor in the hypothalamus, slowing gastric emptying, reducing appetite, and increasing satiety signaling. Adding intensive dietary and psychological support was expected to amplify those mechanisms by addressing behavioral drivers of intake simultaneously.

The primary endpoint, mean percentage change in body weight at week 68, showed a 16.0% reduction with semaglutide plus IBT versus 5.7% with placebo plus IBT, a difference of 10.3 percentage points (P<0.001). [1] Gastrointestinal adverse events were more common in the semaglutide arm (nausea 44.2% vs 19.5%), consistent with findings across the whole STEP program.

How Does STEP 3 Compare to STEP 1?

STEP 1 is the anchor trial of the semaglutide obesity program. It enrolled 1,961 adults without diabetes and delivered semaglutide 2.4 mg with only standard lifestyle advice, producing 14.9% mean weight loss at 68 weeks versus 2.4% with placebo. [2]

STEP 3 added roughly 28 hours of face-to-face counseling, a structured calorie-restricted meal plan, and 150 minutes per week of physical activity guidance. The result was 16.0% weight loss. That 1.1 percentage point gain over STEP 1 may seem modest for the added therapeutic intensity, but the absolute difference is clinically meaningful for some patients. The placebo arm in STEP 3 performed far better (5.7%) than the STEP 1 placebo arm (2.4%), confirming that IBT alone produces real benefit. What STEP 3 clarifies is that semaglutide remains the dominant driver: the drug-minus-placebo difference in STEP 3 (10.3 points) and STEP 1 (12.4 points) are similar, meaning the behavioral program's incremental contribution to the drug effect was comparatively small.

For clinicians deciding between prescribing semaglutide with minimal counseling versus pairing it with a formal IBT program, STEP 3 suggests the additional behavioral investment yields more total weight loss but does not dramatically shift the pharmacological effect size. Patients who cannot access 30-session IBT should not be told to wait before starting semaglutide.

STEP 2: Semaglutide in Adults With Type 2 Diabetes

STEP 2 (Lancet 2021, N=1,210) enrolled adults who had both obesity and type 2 diabetes, a population that typically loses less weight with GLP-1 agonists due to competing physiological factors. [3] At 68 weeks, semaglutide 2.4 mg produced 9.6% mean weight loss versus 3.4% with placebo, and semaglutide 1.0 mg (the standard diabetes dose) produced 7.0%. [3]

The comparison to STEP 3 is instructive. The presence of type 2 diabetes reduced the drug's weight-loss effect by approximately 6.4 percentage points relative to STEP 3. Clinicians treating patients with T2D and obesity should counsel those patients that their absolute weight loss will likely be lower, though the metabolic benefits, including a mean HbA1c reduction of 1.6 percentage points in STEP 2, remain substantial. [3] The FDA approved the Wegovy label specifically covering adults without diabetes and adults with diabetes differently, which reflects this evidence base. [4]

STEP 5: What Happens at Two Years?

Most key obesity trials stop at 68 weeks. STEP 5 (Nature Medicine, 2022, N=304) extended follow-up to 104 weeks with the same semaglutide 2.4 mg dose. [5] Mean weight loss reached 15.2% at week 104 versus 2.6% with placebo. The drug arm did not show meaningful weight regain between weeks 68 and 104 in participants who remained on treatment. This matters for counseling patients about duration: the data from STEP 5 support continued treatment rather than a defined short-course model.

STEP 5 also reported clinically meaningful improvements in waist circumference (down 13.8 cm vs 2.3 cm), systolic blood pressure, and fasting glucose at two years. [5] Gastrointestinal side effects declined in frequency after week 20, addressing a common patient concern about long-term tolerability.

STEP 8: Semaglutide Versus Liraglutide Head-to-Head

STEP 8 (JAMA, 2022, N=338) is the only randomized head-to-head trial comparing two approved GLP-1 agonists for obesity. [6] Semaglutide 2.4 mg once weekly was compared directly to liraglutide 3.0 mg once daily over 68 weeks. Semaglutide produced 15.8% mean weight loss versus 6.4% with liraglutide, a difference of 9.4 percentage points (P<0.001). [6]

Practically, 70.9% of participants on semaglutide achieved at least 10% weight loss versus 25.6% on liraglutide. Liraglutide carries a higher daily injection burden (once daily vs once weekly for semaglutide), which may compound adherence challenges. STEP 8 effectively answered the question that was implicit in clinical practice for years: if a patient can access either agent, semaglutide 2.4 mg produces substantially more weight loss. Liraglutide 3.0 mg (Saxenda) remains an option where cost or access limits semaglutide availability, but the pharmacological hierarchy is now clear.

The Role of Intensive Behavioral Therapy in Modern GLP-1 Practice

IBT in STEP 3 consisted of 30 individual or group counseling sessions, physical activity prescriptions (building to 150-200 minutes per week of moderate-intensity activity), and structured meal replacement for the first eight weeks. The JAMA authors defined IBT based on the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline, which recommends high-intensity intervention of 14 or more face-to-face sessions in the first six months. [7]

In real-world telehealth settings, this level of support is rarely available. Most programs offer monthly check-ins rather than 30 sessions. The STEP 3 data do not support withholding the drug from patients who lack IBT access. They do support investing in behavioral resources when they are available, since the combination produced the highest weight loss of any non-surgical intervention in the STEP program (16.0%), narrowly exceeding STEP 1's 14.9%.

A practical clinical decision framework for integrating STEP 3 evidence:

1. Start semaglutide 2.4 mg dose escalation per the Wegovy FDA-approved schedule (0.25 mg weekly for four weeks, escalating to 2.4 mg by week 16) regardless of behavioral program access. [4]
2. If the patient has access to a structured IBT program (14 or more sessions), enroll them concurrently. STEP 3 shows this adds approximately 1.1 percentage points in additional weight loss beyond STEP 1 conditions.
3. If formal IBT is unavailable, provide at minimum a written meal plan and physical activity target at initiation, consistent with what control arms received across all STEP trials.
4. At 68 weeks, use STEP 5 data to justify ongoing treatment if the patient is maintaining loss. Weight regain accelerates sharply after discontinuation, as shown in the STEP 1 withdrawal extension.
5. For patients with T2D, frame expectations using STEP 2 data (approximately 9.6% vs 16.0% in STEP 3), and highlight HbA1c benefit as a co-primary outcome.

How Semaglutide Compares to Tirzepatide: SURMOUNT Context

No article covering the STEP program in 2024 is complete without positioning semaglutide against tirzepatide (Zepbound, Mounjaro), which acts on both GLP-1 and GIP receptors. SURMOUNT-1 (NEJM, 2022, N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks in adults without diabetes versus 3.1% with placebo. [8] SURMOUNT-2 (Lancet, 2023, N=938) showed 15.7% weight loss in adults with T2D at 72 weeks. [9]

SURMOUNT-3 (Nature Medicine, 2023, N=579) enrolled adults who had already completed a 12-week intensive lifestyle run-in period and then randomized them to tirzepatide or placebo. That arm achieved 18.4% additional weight loss on top of the 2.4% lost during the run-in, for a total of approximately 20.8% from baseline. [10] SURMOUNT-4 (JAMA, 2024) examined maintenance: participants who lost weight on tirzepatide for 36 weeks and then switched to placebo regained 14.8% body weight over 52 weeks versus a 5.5% additional loss in those who stayed on drug. [11]

The head-to-head comparison between semaglutide and tirzepatide has not been done in a fully powered obesity-indication RCT. SURMOUNT-5 is underway. Based on available phase 3 data, tirzepatide 15 mg produces roughly 4-6 percentage points more weight loss than semaglutide 2.4 mg in patients without diabetes. For patients with T2D, the gap is similar. Clinicians should use this information to set expectations and to guide formulary decisions where both agents are accessible.

Safety Profile Across the STEP Trials

Across STEP 1 through STEP 8, the most common adverse events with semaglutide 2.4 mg are gastrointestinal: nausea (reported in 44.2% in STEP 3), diarrhea, vomiting, and constipation. [1] These events peak during dose escalation and decrease over time, as confirmed by the two-year follow-up in STEP 5. [5]

Serious adverse events occurred in 9.8% of the semaglutide arm versus 12.8% of placebo in STEP 3, suggesting no excess serious event risk. [1] The FDA label for Wegovy carries a boxed warning for thyroid C-cell tumors based on rodent data; the clinical relevance in humans remains unestablished, but the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. [4]

The SELECT trial (NEJM, 2023, N=17,604), published after the STEP program concluded, demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in adults with pre-existing cardiovascular disease but without diabetes over a mean 34.2 months of follow-up. [12] The SELECT finding reframes the risk-benefit calculation substantially: for the large population with obesity and cardiovascular disease, the drug now carries both weight-loss and cardiovascular risk-reduction evidence. The AACE/ACE obesity guidelines support pharmacotherapy for patients with BMI at or above 30 kg/m² or at or above 27 kg/m² with comorbidities, aligned with the inclusion criteria across all STEP trials. [13]

Dosing, Access, and What the STEP Program Means for Patients

The FDA-approved dose escalation for Wegovy (semaglutide 2.4 mg) is a 16-week schedule starting at 0.25 mg subcutaneous once weekly and increasing every four weeks to the maintenance dose of 2.4 mg once weekly. [4] All STEP trials used this schedule. Patients who cannot tolerate dose escalation at the standard pace may remain at a lower dose for additional four-week intervals per the FDA label.

Access remains a real barrier. Wegovy's list price exceeded $1,300 per month in the United States as of mid-2024. Compounded semaglutide has been available during shortage periods but carries no FDA approval for efficacy or purity. Patients on commercial insurance with obesity coverage may access the drug at reduced cost; Medicare Part D coverage for obesity medications expanded with the Inflation Reduction Act negotiations, though specific coverage dates vary by plan.

The STEP program collectively enrolled over 4,500 participants across its primary trials, making it one of the most comprehensive obesity pharmacotherapy data sets in medical history. STEP 3 specifically answers the question most relevant to patients already engaged with weight-management programs: adding semaglutide to structured behavioral support produces 16.0% weight loss at 68 weeks, and 86.6% of participants on the drug arm achieved at least 5% weight loss versus 47.6% on placebo plus IBT. [1]

Patients asking whether they need to complete a behavioral program before starting the drug can be directed to STEP 1, which showed 14.9% weight loss with standard lifestyle advice alone. [2] Patients asking how long to stay on treatment can be directed to STEP 5, which showed weight maintenance at 104 weeks with no signal of diminishing efficacy. [5] Patients comparing semaglutide to liraglutide can be directed to STEP 8. [6]

The mean weight loss in STEP 3 (16.0%) approaches the threshold historically associated with bariatric surgery in some populations, a fact that has reshaped how obesity medicine specialists frame pharmacotherapy in clinical conversations.